Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visio-AMTRIX in Recurrent Macular Hole
NCT05191628Phase 2Terminated
- Sponsor
- TBF Génie Tissulaire
- Start
- Jun 2020
- Primary completion
- Oct 2022
- Modality
- Device-based Delivery, Tissue Cells
- Countries
- 1
01
Overview
A Phase 2 trial of LV-Visio-AMTRIX in macular hole, retinal detachment, sponsored by TBF Génie Tissulaire. Started Jun 2020; status: terminated.
02
Drugs
LV-Visio-AMTRIX
03
Conditions
macular holeretinal detachment
Beyond the preview
Go deeper on NCT05191628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191628.